仙琚制药(002332.SZ)：甲硫酸新斯的明注射液通过仿制药一致性评价

智通财经10-14

智通财经APP讯，仙琚制药(002332.SZ)发布公告，公司于近日收到国家药品监督管理局核准签发的关于甲硫酸新斯的明注射液的《药品补充申请批准通知书》(通知书编号：2024B047132024B04714)，公司甲硫酸新斯的明注射液通过仿制药质量和疗效一致性评价。据悉，甲硫酸新斯的明注射液是抗胆碱酯酶药。用于手术结束时拮抗非去极化肌肉松弛药的残留肌松作用，用于重症肌无力，手术后功能性肠胀气及...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2475334729?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-10-14 16:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2475334729","market":"us","top_or_hot":-1,"title":"仙琚制药(002332.SZ)：甲硫酸新斯的明注射液通过仿制药一致性评价","media":"智通财经","content":"<div>\n<p>智通财经APP讯，仙琚制药(002332.SZ)发布公告，公司于近日收到国家药品监督管理局核准签发的关于甲硫酸新斯的明注射液的《药品补充申请批准通知书》(通知书编号：2024B047132024B04714)，公司甲硫酸新斯的明注射液通过仿制药质量和疗效一致性评价。据悉，甲硫酸新斯的明注射液是抗胆碱酯酶药。用于手术结束时拮抗非去极化肌肉松弛药的残留肌松作用，用于重症肌无力，手术后功能性肠胀气及...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1193358.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>仙琚制药(002332.SZ)：甲硫酸新斯的明注射液通过仿制药一致性评价</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n仙琚制药(002332.SZ)：甲硫酸新斯的明注射液通过仿制药一致性评价\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-14 16:22 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1193358.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，仙琚制药(002332.SZ)发布公告，公司于近日收到国家药品监督管理局核准签发的关于甲硫酸新斯的明注射液的《药品补充申请批准通知书》(通知书编号：2024B047132024B04714)，公司甲硫酸新斯的明注射液通过仿制药质量和疗效一致性评价。据悉，甲硫酸新斯的明注射液是抗胆碱酯酶药。用于手术结束时拮抗非去极化肌肉松弛药的残留肌松作用，用于重症肌无力，手术后功能性肠胀气及...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1193358.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"002332","symbol_name":"仙琚制药","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1193358.html","article_id":"2475334729","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2475334729","pubTimestamp":1728894167,"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，仙琚制药(002332.SZ)发布公告，公司于近日收到国家药品监督管理局核准签发的关于甲硫酸新斯的明注射液的《药品补充申请批准通知书》(通知书编号：2024B047132024B04714)，公司甲硫酸新斯的明注射液通过仿制药质量和疗效一致性评价。据悉，甲硫酸新斯的明注射液是抗胆碱酯酶药。用于手术结束时拮抗非去极化肌肉松弛药的残留肌松作用，用于重症肌无力，手术后功能性肠胀气及尿潴留等。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"002332":"仙琚制药","BK0028":"国家队","BK0239":"医药制造","SG9999014674.SGD":"Nikko AM All China Equity A SGD"},"translate_title":"Xianju Pharmaceutical (002332. SZ): Neostigmine mesulfate injection passed the consistency evaluation of generic drugs","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"002332":1},"content_text":"智通财经APP讯，仙琚制药(002332.SZ)发布公告，公司于近日收到国家药品监督管理局核准签发的关于甲硫酸新斯的明注射液的《药品补充申请批准通知书》(通知书编号：2024B047132024B04714)，公司甲硫酸新斯的明注射液通过仿制药质量和疗效一致性评价。据悉，甲硫酸新斯的明注射液是抗胆碱酯酶药。用于手术结束时拮抗非去极化肌肉松弛药的残留肌松作用，用于重症肌无力，手术后功能性肠胀气及尿潴留等。","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2475334729"}